Dr. Yasser Ged, MD

Dr. Ged practices at Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland.

Dr. Ged's NPI, 1952811044, was assigned on October 3, 2017. Dr. Ged holds Maryland license D88423.

Dr. Ged's primary practice is Johns Hopkins Hospital Nelson/Harvey Building, at 600 N Wolfe St, Baltimore, MD 21287 in Baltimore City. The practice phone is (855) 662-3017.

Dr. Ged's primary practice is Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland. Dr. Ged is also affiliated with The Johns Hopkins Hospital. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Ged to 1 more hospital, 2 group practices and clinics, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ged practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Ged's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Ged's licenses on file in 2 states: Maryland and New York.

CMS data shows 650 Medicare services from Dr. Ged across 5 procedure codes in 2024, for 144 Medicare patients. Medicare paid $45,791 for them.

CMS counts 144 Medicare patients who saw Dr. Ged in 2024. The largest group is 65 to 74, with 75 patients. 75% of them have cancer, and 75% have high blood pressure. 13% are also on Medicaid. Their average risk score is 2.75, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ged's median patient age at 71, with 25% women.

In 2024, Dr. Ged wrote 324 Medicare Part D claims for 42 patients. 48% of them were for generic drugs. CMS names the drug for 193 of them, across 7 drugs with 11 or more claims each, at $2,993,484 in total drug cost. In 2023, CMS named 130 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Ged for performance year 2024, reported as part of a group. CMS lists Dr. Ged as offering telehealth.

Dmand AI links 49 papers to Dr. Ged, published from 2016 to 2025. 2024 was the busiest year, with 9. The most frequent topics are Carcinoma, Renal Cell, Kidney Neoplasms and Immune Checkpoint Inhibitors. Dr. Ged has published most often in Kidney Cancer J. Dr. Ged's most frequent co-authors are Robert J. Motzer, MD, Nirmish Singla, MD and Martin Henner Voss, MD.

Dmand AI links Dr. Ged to 2 clinical trials. 1 is still active or recruiting. Conditions studied include COVID-19 and Pneumonia, Viral. Open Payments lists research payments to Dr. Ged that name 2 trials.

CMS Open Payments shows 49 general payments to Dr. Ged from 7 drug and device companies from 2021 to 2025. Consulting fees make up the largest share, 45% of the total. Exelixis Inc. paid the most, $13,623. It also lists 3 research payments totaling $6,200 from 2024 to 2025, naming 2 clinical trials.